Attitudes of European psychiatrists on psychedelics: a qualitative study

被引:0
作者
Zuljevic, Marija Franka [1 ]
Breski, Nando [2 ]
Kaliterna, Mariano [1 ]
Hren, Darko [2 ]
机构
[1] Univ Split, Sch Med, Dept Med Humanities, Split, Croatia
[2] Univ Split, Fac Humanities & Social Sci, Dept Psychol, Split, Croatia
来源
FRONTIERS IN PSYCHIATRY | 2024年 / 15卷
基金
美国国家卫生研究院;
关键词
psychedelics; psychedelic therapy; psilocybin; MDMA; attitudes; psychiatrists; DRUGS;
D O I
10.3389/fpsyt.2024.1411234
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Introduction and aim It is important to understand how mental health practitioners view recent findings on psychedelic-assisted psychotherapy (PAP) as there is potential this treatment may be incorporated into clinical practice. The aim of our study was to explore how psychiatrists who are not involved in psychedelic research and who are located in the European region perceive psychedelics and PAP.Methods We conducted online semi-structured interviews with 12 psychiatry specialists and psychiatry trainees from 8 European countries. Data were analyzed using a general inductive approach informed by codebook thematic analysis.Results Based on the interviews, we developed four main themes and 14 sub-themes, including (1) Psychedelics hold potential, (2) Psychedelics are dangerous, (3) Future of psychedelics is uncertain, and (4) Psychiatry is ambivalent toward psychedelics.Discussion Our respondents-psychiatrists acknowledged the potential of PAP but remained cautious and did not yet perceive its evidence base as robust enough. Education on psychedelics is lacking in medical and psychiatric training and should be improved to facilitate the involvement of mental health experts in decision-making on PAP.
引用
收藏
页数:14
相关论文
共 38 条
  • [1] Long-term effects of psychedelic drugs: A systematic review
    Aday, Jacob S.
    Mitzkovitz, Cayla M.
    Bloesch, Emily K.
    Davoli, Christopher C.
    Davis, Alan K.
    [J]. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2020, 113 : 179 - 189
  • [2] Patterns of use, desired effects, and mental health status of a sample of natural psychoactive drug users
    Aixala, Marc
    Ona, Genis
    Pares, Oscar
    Carlos Bouso, Jose
    [J]. DRUGS-EDUCATION PREVENTION AND POLICY, 2020, 27 (03) : 191 - 198
  • [3] Anderson BT, 2020, LANCET PSYCHIAT, V7, P829, DOI 10.1016/S2215-0366(20)30146-2
  • [4] [Anonymous], 2023, European Drug Report 2023: Trends and Developments
  • [5] United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020
    Barnett, Brian S.
    Parker, Sloane E.
    Weleff, Jeremy
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2022, 99
  • [6] Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey
    Barnett, Brian S.
    Beaussant, Yvan
    King, Franklin
    Doblin, Rick
    [J]. JOURNAL OF PSYCHOACTIVE DRUGS, 2022, 54 (03) : 269 - 277
  • [7] A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens
    Barnett, Brian S.
    Siu, Willie O.
    Pope, Harrison G.
    [J]. JOURNAL OF NERVOUS AND MENTAL DISEASE, 2018, 206 (06) : 476 - 480
  • [8] Mapping an Agenda for Psychedelic-Assisted Therapy Research in Patients with Serious Illness
    Beaussant, Yvan
    Tulsky, James
    Guerin, Benjamin
    Schwarz-Plaschg, Claudia
    Sanders, Justin J.
    [J]. JOURNAL OF PALLIATIVE MEDICINE, 2021, 24 (11) : 1657 - 1666
  • [9] Fentanyl panic goes viral: The spread of misinformation about overdose risk from casual contact with fentanyl in mainstream and social media
    Beletsky, Leo
    Seymour, Sarah
    Kang, Sunyou
    Siegel, Zachary
    Sinha, Michael S.
    Marino, Ryan
    Dave, Aashka
    Freifeld, Clark
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2020, 86
  • [10] Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [DOI 10.1080/14780887.2020.1769238, 10.1191/1478088706qp063oa]